Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: evidence from the JINGO project
Ward M, Hughes CF, Strain JJ, Reilly R, Cunningham C, Molloy AM, et al.
Published in BMC Med, Vol. 18 (1), pp. 318
Methodology
Observational analysis of 6,076 adults aged 18-102 from two Irish cohorts (TUDA and the National Adult Nutrition Survey), relating MTHFR C677T genotype and riboflavin biomarker status to blood pressure and hypertension.
Key Findings
12% of adults had the TT genotype. From 18 to 70 years, TT was linked to higher hypertension risk (OR 1.42, 95% CI 1.07-1.90). TT combined with deficient riboflavin status carried a 3-fold risk (OR 3.00, 95% CI 1.34-6.68) versus CC with normal riboflavin. Blood pressure control on treatment was 30% in TT vs 45% in CC up to 65 years.
Conclusions
The TT genotype predisposes to hypertension and poorer control on treatment, and better riboflavin status is associated with a reduced genetic risk.
Limitations
Cross-sectional associations cannot show that riboflavin lowers risk; partly a volunteer sample; Irish population with no mandatory fortification.
Supplements Studied
better riboflavin status is associated with a reduced genetic risk
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.